28 results
DEFM14A
KRTX
Karuna Therapeutics Inc
5 Feb 24
Proxy related to merger
4:12pm
and employees, and the risks associated with continued independence discussed below.
Product development and commercialization risks. The Karuna Board … affecting the revenues and profitability of product candidates generally.
Risks associated with continued independence. While the Karuna Board remained
PREM14A
KRTX
Karuna Therapeutics Inc
22 Jan 24
Preliminary proxy related to merger
6:05am
, financial and execution risks, its relationships with suppliers, collaborators and employees, and the risks associated with continued independence … .
Risks associated with continued independence. While the Karuna Board remained supportive of Karuna’s strategic plan and optimistic about its
S-3ASR
EX-1.2
KRTX
Karuna Therapeutics Inc
21 Jun 23
Automatic shelf registration
5:15pm
(the “Board”) meets the independence requirements of, and has established an audit committee, a compensation committee and a nominating and corporate … governance committee, in each case, that meets the independence requirements of, the rules and regulations of the SEC and the Exchange, including the phase
8-K
EX-1.1
vr9pq 3emjg2ayfg
11 Aug 22
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
5:03pm
8-K
EX-99.1
9g5ecb6
10 Mar 21
Entry into a Material Definitive Agreement
4:47pm
8-K
EX-1.1
0k5xc7x206
3 Mar 21
Karuna Announces Proposed Public Offering of Common Stock
5:10pm
S-3ASR
EX-1.2
mkqes2 twb8f7pq
2 Jul 20
Automatic shelf registration
4:19pm
DEF 14A
yqb8lgd vj7f
29 Apr 20
Definitive proxy
4:00pm
10-K
5r2r18b w3oho
24 Mar 20
Annual report
6:32am
424B4
2xhowen1n1p46uyfnzb4
21 Nov 19
Prospectus supplement with pricing info
4:02pm
DRS
naxv1sicon9i
28 Oct 19
Draft registration statement
12:00am